<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088577</url>
  </required_header>
  <id_info>
    <org_study_id>754-2018</org_study_id>
    <secondary_id>111580763245</secondary_id>
    <nct_id>NCT05088577</nct_id>
  </id_info>
  <brief_title>Evaluation of Egg Consumption and Its Enrichment With Annatto on Cardiovascular Risk and Satiety in Healthy Adults</brief_title>
  <acronym>EGGANT</acronym>
  <official_title>Evaluation of the Effects of Egg Consumption and Its Enrichment With Annatto on Biomarkers of Cardiovascular Risk and Satiety in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy adult volunteers (n= 105; 18-59 years) were randomly allocated to consume daily for 8&#xD;
      weeks, either two whole eggs (egg group), two whole eggs added with annatto (annatto-enriched&#xD;
      egg group), or two egg whites (control). Volunteers were asked to continue with the habitual&#xD;
      physical activity and diet, except for the consumption of additional eggs, egg whites or&#xD;
      annatto.&#xD;
&#xD;
      It is hypothesized that participants consuming eggs would have a less atherogenic lipid&#xD;
      profile, feel more satisfied and increase antioxidant levels in blood, compared to the&#xD;
      control group. Participants in the annatto-enriched egg group would have greater antioxidant&#xD;
      capacity than the egg group and compared to control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Change from Baseline Total cholesterol at 8 weeks</time_frame>
    <description>Fasting blood total cholesterol in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Change from Baseline LDL cholesterol at 8 weeks</time_frame>
    <description>Fasting blood LDL cholesterol in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very low-density lipoprotein (VLDL) cholesterol</measure>
    <time_frame>Change from Baseline VLDL cholesterol at 8 weeks</time_frame>
    <description>Fasting blood VLDL cholesterol in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Change from Baseline Triglycerides at 8 weeks</time_frame>
    <description>Fasting blood triglycerides in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density lipoprotein (HLDL) cholesterol</measure>
    <time_frame>Change from Baseline HDL cholesterol at 8 weeks</time_frame>
    <description>Fasting blood HLDL cholesterol in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>Change from Baseline Glucose at 8 weeks</time_frame>
    <description>Fasting blood glucose in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Change from Baseline Systolic Blood Pressure at 8 weeks</time_frame>
    <description>Systolic blood pressure in mmHg will be used to present the results of this variable, as follow: e.g. 130 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Change from Baseline Diastolic Blood Pressure at 8 weeks</time_frame>
    <description>Diastolic blood pressure in mmHg will be used to present the results of this variable, as follow: e.g. 85 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI) in kg/m^2: weight in kilograms, height in meters</measure>
    <time_frame>Change from Baseline BMI at 8 weeks</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Change from Baseline Waist circumference at 8 weeks</time_frame>
    <description>Waist circumference in centimeters measured at the superior border of the iliac crest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood lutein levels</measure>
    <time_frame>Change from Baseline Blood lutein levels at 8 weeks</time_frame>
    <description>Fasting blood lutein levels in micrograms per mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dietary lutein+zeaxanthin levels</measure>
    <time_frame>Change from Baseline Dietary lutein+zeaxanthin levels at 8 weeks</time_frame>
    <description>Dietary lutein+zeaxanthin levels in micrograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood bixin levels</measure>
    <time_frame>Change from Baseline Blood bixin levels at 8 weeks</time_frame>
    <description>Fasting blood bixin levels in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglyceride-Rich lipoprotein (TRLP) size</measure>
    <time_frame>Change from Baseline TRLP size at 8 weeks</time_frame>
    <description>Fasting blood subclasses (Large, medium, small) of TRLP in nmol/L measured by Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein (LDL) size</measure>
    <time_frame>Change from Baseline LDL size at 8 weeks</time_frame>
    <description>Fasting blood subclasses (Large, medium, small) of LDL in nmol/L measured by Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density lipoprotein (HDL) size</measure>
    <time_frame>Change from Baseline HDL size at 8 weeks</time_frame>
    <description>Fasting blood subclasses (Large, medium, small) of HDL in μmol/L measured by Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein B (ApoB)</measure>
    <time_frame>Change from Baseline ApoB at 8 weeks</time_frame>
    <description>Fasting blood ApoB in mg/L measured by Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein A1 (ApoA1)</measure>
    <time_frame>Change from Baseline ApoA1 at 8 weeks</time_frame>
    <description>Fasting blood ApoA1 in mg/L measured by Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>Change from Baseline Ghrelin at 8 weeks</time_frame>
    <description>Ghrelin in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) to Measure Perceived Hunger and Satiety</measure>
    <time_frame>Change from Baseline VAS of Hunger and Satiety at 8 weeks</time_frame>
    <description>&quot;Visual Analog Scale to measure perceived hunger and satiety&quot; to complete in the morning, fasting, 5 days before entering the study and the last 5 days to end the study (8th week). The VAS consist of 8 questions followed each by a line of 10cm in which the person marks a position corresponding to his/her feelings about hunger and satiety. A higher score (10) means the person feels with more hunger or satisfied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ancestry Informative Marker</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of genetic ethnicity of European, Amerindian and African for each participant</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Whole egg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two whole eggs (50g each) to be eaten daily during 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Annatto-enriched egg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two whole eggs (50g each) enriched with annatto (Bixa orellana L.) to be eaten daily during 8 weeks. Dose of annatto: 1,2 mg bixin/kg of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egg whites - Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two egg whites to be eaten daily during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whole egg</intervention_name>
    <description>Daily consumption of two whole eggs during 8 weeks</description>
    <arm_group_label>Whole egg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Annatto-enriched egg</intervention_name>
    <description>Daily consumption of two whole eggs enriched with annatto during 8 weeks</description>
    <arm_group_label>Annatto-enriched egg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Egg whites - Control</intervention_name>
    <description>Daily consumption of two eggs whites during 8 weeks</description>
    <arm_group_label>Egg whites - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-59 years&#xD;
&#xD;
          -  Body Mass Index (BMI): 18,5 - 29,9 kg/m2&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Good disposition to consume either eggs, egg whites or eggs added with annatto&#xD;
&#xD;
          -  To have signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting blood triglycerides &gt; 500mg/dL, Total Cholesterol &gt; 240mg/dL, glucose &gt;&#xD;
             126mg/dL or diabetes.&#xD;
&#xD;
          -  Blood pressure: &gt;140/90 mmHg.&#xD;
&#xD;
          -  History or having any of the following: liver, kidney, or heart disease, cancer,&#xD;
             endocrine or gastrointestinal disorders -especially those that limit food absorption.&#xD;
&#xD;
          -  Use of medications to lower blood lipids or glucose.&#xD;
&#xD;
          -  Consumption of multivitamins or nutraceuticals.&#xD;
&#xD;
          -  Plan to lose body weight, pregnancy or breastfeeding.&#xD;
&#xD;
          -  Any known allergy or intolerance to eggs or annatto.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Barona-Acevedo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sede de Investigación Universitaria - Universidad de Antioquia</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Antioquia</investigator_affiliation>
    <investigator_full_name>Jacqueline Barona Acevedo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Egg</keyword>
  <keyword>Bixa orellana</keyword>
  <keyword>Annatto</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>clinical trial</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

